Drug Development


The FDA has issued its approval to a new skin care drug called Cosentyx (secukinumab) aimed at treating plaque psoriasis. The condition is an autoimmune disorder that causes itchy, irritated skin and is most common in adults aged 15 to 35. The new drug works by binding to a protein called interleukin (IL)-17A. In doing so, it prevents that protein from reaching its receptor.

Medicines-122314.jpg Prostate cancer is one of the most dreaded forms of the disease - a major problem in men's health and in the medical community generally. Recent study results released by Medivation Inc. (MDVN) and Astellas Pharma showed that a mid-stage trial of an experimental drug showed some progress. Here a few advancements (and one step back) in the battle to alleviate prostate cancer.

savaysa-011215.jpg A new anti-clotting drug, Savaysa (edoxaban), which reduces the risk of dangerous blood clots and strokes in people with a type of heart rhythm disorder, has been approved by the U.S. Food and Drug Administration. The new drug was approved to treat people with atrial fibrillation that's not caused by a heart valve problem.

hypodermicneedle-052812_10Jul12.jpg The FDA has issued approval to a new human papillomavirus (HPV) vaccine called Gardasil 9. The name suggests the vaccine prevents the administration of nine different forms of HPV and is recommended for use in boys and girls at the ages 11 and 12. "Gardasil 9 has the potential to prevent approximately 90 percent of cervical, vulvar, vaginal and anal cancers," the FDA said.

AlzheimerAssociation-040611.jpg A new combo pill has been approved by the FDA to treat Alzheimer's disease in people being treated by both drugs. The pill, called Nanzaric, is taken once a day and can be sprinkled on food for patients who have trouble swallowing. It is meant to treat moderate to severe Alzheimer's disease and combines memantine hydrochloride extended-release (Namenda) and donepezil hydrochloride (Aricept).

Follow RTT